Disease · MONDO_0004982
pancreatitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. pancreatitis. Diseases, record MONDO_0004982. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004982
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Pancreatic inflammation, Pancreatitides, Pancreatitis (disorder), Pancreatitis NOS, inflammation of pancreas, pancreas inflammation
- Open Targets
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| EUPATILIN | CHEMBL312750 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| GABEXATE | CHEMBL87563 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| ICOSAPENT ETHYL | CHEMBL2095209 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| METHANTHELINE | CHEMBL1201264 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| NAFAMOSTAT | CHEMBL273264 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| ACETAMINOPHEN | CHEMBL112 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BUPIVACAINE | CHEMBL1098 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OLEZARSEN | CHEMBL4650438 | Oligonucleotide | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALIPOGENE TIPARVOVEC | CHEMBL2108304 | Gene | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SIMVASTATIN | CHEMBL1064 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets8
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| APOC3 | Apolipoprotein C-III mRNA | 1 | Apolipoprotein C-III mRNA antisense inhibitor | Phase 3 | https://conductscience.org/library/genes/345 | Drugs and targets |
| FAAH | Fatty-acid amide hydrolase 1 | 1 | Anandamide amidohydrolase inhibitor | Phase 3 | https://conductscience.org/library/genes/2166 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 1 | HMG-CoA reductase inhibitor | Phase 2 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| HRH2 | Histamine H2 receptor | 1 | Histamine H2 receptor antagonist | Approval | https://conductscience.org/library/genes/3274 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| SCN4A | Sodium channel protein type 4 subunit alpha | 1 | Sodium channel protein type IV alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| TRPV1 | Transient receptor potential cation channel subfamily V member 1 | 1 | Vanilloid receptor opener | Phase 3 | https://conductscience.org/library/genes/7442 | Drugs and targets |
Trials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02743364 | Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis | Phase 2 | 8 | 2022-01-04 | Acute Pancreatitis | SIMVASTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT05079919 | A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia | Phase 3 | 617 | Severe Hypertriglyceridemia | OLEZARSEN | Its record names the disease | ClinicalTrials.gov | |
| NCT04195347 | Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase | Phase 1/2 | 42 | Acute Pancreatitis | ZEGOCRACTIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04767542 | Postoperative Pain Difference for 'IV Paracetamol' and TAP Block' in Acute Cholecystitis | Phase 3 | 42 | Transversus Abdominis Plane (TAP) Block | ACETAMINOPHEN, BUPIVACAINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00891306 | Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects | Phase 2/3 | 5 | Familial Lipoprotein Lipase Deficiency | ALIPOGENE TIPARVOVEC | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm I (Simvastatin) vs Arm II (Placebo): deaths from any cause | 0 of 6 | 0 of 2 | 8 | NCT02743364 | Trial comparisons |
| Arm I (Simvastatin) vs Arm II (Placebo): Pancreatitis-related Readmissions | 5 of 6 | 1 of 2 | 8 | NCT02743364 | Trial comparisons |
| Arm I (Simvastatin) vs Arm II (Placebo): serious adverse events | 5 of 6 | 1 of 2 | 8 | NCT02743364 | Trial comparisons |
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004982
GET https://conductscience.org/api/diseases/v1/MONDO_0004982/drugs